Showing results (481-490 of 601) with videos related to

Sort By:
Pageof 61
Cells|March 27, 2024
Recombinant Acetylcholine Receptor Immunization Induces a Robust Model of Experimental Autoimmune Myasthenia Gravis in MiceLukas Theissen, Christina B Schroeter, Niklas Huntemann, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trialGiancarlo Comi, Ludwig Kappos, Krzysztof W Selmaj, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 29, 2022
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trialBruce Ac Cree, Krzysztof W Selmaj, Lawrence Steinman, et al.
JAMA Neurology|October 13, 2015
Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1bKathryn C Fitzgerald, Kassandra L Munger, Karl Köchert, et al.
The Lancet. Neurology|September 8, 2019
Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trialJeffrey A Cohen, Giancarlo Comi, Krzysztof W Selmaj, et al.
Drugs|December 18, 2007
Pharmacological treatment of early multiple sclerosisOlaf Stüve, Jeffrey L Bennett, Bernhard Hemmer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 22, 2023
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trialRobert T Naismith, Jeffrey A Cohen, Amit Bar-Or, et al.
Annals of Clinical and Translational Neurology|October 7, 2023
Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphismHo Jin Kim, Orhan Aktas, Kristina R Patterson, et al.
Annals of Neurology|November 12, 2005
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria"Chris H Polman, Stephen C Reingold, Gilles Edan, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 12, 2013
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndromeGijsbert J A Nagtegaal, Christoph Pohl, Mike P Wattjes, et al.
Pageof 61